Patient on allergen immunotherapy developed systemic lupus erythematosus?– A clinico-pharmacological look out

Mukherjee, Shatavisa; Samajdar, Shambo Samrat; Basu, Kaushik; Moitra, Saibal; Tripath, Santanu K

doi:10.18231/j.ijor.2021.020

Cited by 1 publication

(2 citation statements)

References 12 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reason for the lack of studies was speculated to be that allergists are generally reluctant to perform AIT in patients with allergic rhinitis complicated by RADs [ 6 ]. Certainly, there are several reports on the appearance of autoimmune diseases such as rheumatoid arthritis [ 22 ], systemic lupus erythematosus [ 23 ], Sjogren’s syndrome [ 24 ], and vasculitis after AIT [ 25 , 26 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and safety of allergen immunotherapy in patients with allergic rhinitis complicated by rheumatic autoimmune diseases: a case series study

Fujioka

Kasahara

Kida

et al. 2022

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

Background Allergen immunotherapy (AIT) is the only treatment that has modified the natural history of allergic diseases. However, since its overall effect on the immune system has not been elucidated, AIT is either absolutely or relatively contraindicated in patients with rheumatic autoimmune diseases (RADs). Therefore, there have been no long-term observations of patients with RADs receiving AIT; thus, the effectiveness and safety of AIT in these patients remain unclear. Methods This was a single-center retrospective observational study. RAD patients receiving AIT for allergic rhinitis at our institution were selected. Changes in the activity of RAD patients were investigated for 2 years from baseline, including those who discontinued AIT. The effectiveness of AIT was also investigated using the Japan Allergic Rhinitis Standard Quality of Life Questionnaire. Results Thirteen patients with RADs were enrolled in the study. All patients received sublingual immunotherapy, of which four discontinued AIT owing to adverse events. Among all patients, the symptoms of RADs in three patients worsened during the observation period; however, none of them were causally related to AIT. Most of the adverse events associated with AIT were mild, in which only one patient required drug intervention due to worsening rhinitis symptoms. In the nine patients who were able to continue AIT, their eye and nasal symptom scores showed a significant improvement from 1.67 (1.5–2.0) at baseline to 0.67 (0–1.17) in the 2nd year of treatment (p = 0.0141). Conclusions AIT is a safe and effective treatment modality for patients with allergic rhinitis complicated by RADs.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Certainly, there are several reports on the appearance of autoimmune diseases such as rheumatoid arthritis [22], systemic lupus erythematosus [23], Sjogren's syndrome [24], and vasculitis after AIT [25,26].…”

Section: Discussionmentioning

confidence: 99%